کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3852322 | 1598382 | 2006 | 11 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Once-Every-2-Weeks and Once-Weekly Epoetin Beta Regimens: Equivalency in Hemodialyzed Patients
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
بیماریهای کلیوی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Once-Every-2-Weeks and Once-Weekly Epoetin Beta Regimens: Equivalency in Hemodialyzed Patients Once-Every-2-Weeks and Once-Weekly Epoetin Beta Regimens: Equivalency in Hemodialyzed Patients](/preview/png/3852322.png)
چکیده انگلیسی
Background: Currently, less frequent than once-weekly subcutaneous epoetin administration regimens were shown to be equally effective and safe as once-weekly schedules in stable predialysis and peritoneal dialysis patients. Bioequivalency of once-every-2-weeks and once-weekly subcutaneous administration of the same total dose of epoetin beta for the maintenance phase of anemia treatment in stable iron-replete long-term hemodialysis patients therefore was investigated prospectively. Methods: Two hundred seven stable selected hemodialysis patients without diabetes, acute illness, significant inflammation, malnutrition or hyperparathyroidism administered once-weekly subcutaneous epoetin beta and preserving stable hemoglobin levels between 10 and 12 g/dL (100 and 120 g/L; difference between maximum and minimum of 3 subsequent levels â¤2.5 g/dL [â¤25 g/L]) and optimal iron status for at least 8 weeks before inclusion were enrolled and randomly assigned to subcutaneous administration of the same total dose of epoetin beta either once every 2 weeks (group 2w; n = 104) or once weekly (group 1w; n = 103) for 24 weeks. Results: Per-protocol analyses (group 1w = 102 versus group 2w = 101) showed similar hemoglobin levels throughout the assessment period (weeks 13 to 24): mean, 11.38 g/dL; 95% confidence interval (CI), 11.23 to 11.54 versus 11.41 g/dL; 95% CI, 11.22 to 11.58. Mean difference was 0.028 g/dL (95% CI, â0.208 to 0.264) in the prespecified range (±0.5 g/dL). Epoetin dose ratio of group 2w to group 1w was 0.94 (95% CI, 0.813 to 1.076), also in the prespecified range of equivalence (0.80 to 1.25). Hemoglobin levels and epoetin doses were stable during the study irrespective of treatment schedule, with no differences between groups at any time. Both schedules were well tolerated. Conclusion: Once-every-2-weeks and once-weekly subcutaneous epoetin beta regimens are equivalent in the maintenance phase of anemia treatment in long-term stable hemodialysis patients without diabetes, with similar safety profiles.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: American Journal of Kidney Diseases - Volume 48, Issue 3, September 2006, Pages 445-455
Journal: American Journal of Kidney Diseases - Volume 48, Issue 3, September 2006, Pages 445-455
نویسندگان
Gabriel MD, PhD, Liliana MD, PhD, Alexandru MD, PhD, Ovidiu MD, PhD, Mirela MD, PhD, Dimitrie MD, PhD, Eugen MD, PhD, Paul MD, Adrian MD, Simona MD, Niculae MD, MSc, Adrian Constantin MD, PhD,